AIM ImmunoTech Inc.
| AMEX: AIM |
| Healthcare / Biotechnology / USA |
| 0.8400 | +0.0100 | +1.20% | Vol 78.05K | 1Y Perf -62.27% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 0.8348 | ASK | 0.8740 | ||
| Open | 0.8500 | Previous Close | 0.8300 | ||
| Pre-Market | - | After-Market | 0.83 | ||
| - - | -0.01 -1.19% |
| Target Price | 3.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 257.14 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★+ 60.49 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★+ 55.23 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 17.37 | Earnings Rating | — | |
| Market Cap | 33.34M | Earnings Date | 16th Aug 2022 | |
| Alpha | -0.01 | Standard Deviation | 0.27 | |
| Beta | -0.58 |
Today's Price Range 0.82840.8650 | 52W Range 0.55002.22 | 5 Year PE Ratio Range -1.70-1.50 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 3.70% | ||
| 1 Month | -6.87% | ||
| 3 Months | -24.32% | ||
| 6 Months | -23.64% | ||
| 1 Year | -62.27% | ||
| 3 Years | -80.56% | ||
| 5 Years | -96.10% | ||
| 10 Years | -99.95% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -35.34 | |||
ROE last 12 Months | -32.57 | |||
ROA (5Y Avg) | -13.20 | |||
ROA last 12 Months | -31.21 | |||
ROC (5Y Avg) | -53.43 | |||
ROC last 12 Months | -30.91 | |||
Return on invested Capital Q | -7.09 | |||
Return on invested Capital Y | -9.93 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.00 | ||||
| 0.74 | ||||
| 231.29 | ||||
| - | ||||
| -2.80 | ||||
| -0.29 | ||||
| 0.77 | ||||
| 1.09 | ||||
| -4 764 460.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 60.30 | ||||
| 65.80 | ||||
| 0.00 | ||||
| 0.00 | ||||
| -1 138.30 | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -392.90 | ||||
| -13 822.10 | ||||
| -13 410.00 | ||||
| -6 361.50 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 139.00K | ||||
| 0.00 | ||||
| -16.96 | ||||
| -12.96 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2021 | - | -0.08 | - |
| Q02 2021 | - | -0.12 | - |
| Q01 2021 | - | -0.08 | - |
| Q04 2020 | - | -0.09 | - |
| Q03 2020 | - | -0.08 | - |
| Q02 2020 | - | -0.11 | - |
| Q01 2020 | - | -0.22 | - |
| Q03 2019 | - | -1.13 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 16th Aug 2022 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 78.05K |
| Shares Outstanding | 39.69K |
| Shares Float | 47.43M |
| Trades Count | 247 |
| Dollar Volume | 66.19K |
| Avg. Volume | 278.47K |
| Avg. Weekly Volume | 145.72K |
| Avg. Monthly Volume | 179.80K |
| Avg. Quarterly Volume | 509.90K |
AIM ImmunoTech Inc. (AMEX: AIM) stock closed at 0.84 per share at the end of the most recent trading day (a 1.2% change compared to the prior day closing price) with a volume of 78.05K shares and market capitalization of 33.34M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. AIM ImmunoTech Inc. CEO is Thomas K. Equels.
The one-year performance of AIM ImmunoTech Inc. stock is -62.27%, while year-to-date (YTD) performance is -8.7%. AIM stock has a five-year performance of -96.1%. Its 52-week range is between 0.55 and 2.22, which gives AIM stock a 52-week price range ratio of 17.37%
AIM ImmunoTech Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 0.74, a price-to-sale (PS) ratio of 231.29, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.21%, a ROC of -30.91% and a ROE of -32.57%. The company’s profit margin is -%, its EBITDA margin is -13 410.00%, and its revenue ttm is $139.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from AIM ImmunoTech Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AIM ImmunoTech Inc.’s next earnings report date is 16th Aug 2022.
The consensus rating of Wall Street analysts for AIM ImmunoTech Inc. is Strong Buy (1), with a target price of $3, which is +257.14% compared to the current price. The earnings rating for AIM ImmunoTech Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AIM ImmunoTech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AIM ImmunoTech Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.99, ATR14 : 0.06, CCI20 : -47.40, Chaikin Money Flow : -0.48, MACD : -0.04, Money Flow Index : 65.57, ROC : -3.55, RSI : 42.14, STOCH (14,3) : 27.34, STOCH RSI : 1.00, UO : 28.68, Williams %R : -72.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AIM ImmunoTech Inc. in the last 12-months were:
AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
CEO: Thomas K. Equels
Telephone: +1 352 448-7797
Address: 2117 SW Highway 484, Ocala 34473, FL, US
Number of employees: 23
TipRanks News for AIM
Thu, 19 May 2022 14:25 GMT AIM ImmunoTech (AIM) Has a New Rating from Maxim Group
- TipRanks. All rights reserved.
